• Home
  • Our Pipeline
  • About Us
  • Our Team
  • News
  • Contact Us

Focused on the discovery of new treatments for under-served skin diseases





The best online cover web page in the market





Jack Nash, CEO & Founder, Example Company



Our story





We are a privately funded clinical stage pharmaceutical company with multiple compounds in development that were discovered at Emory University. We are a capital efficient company and in addition to private investors we have received significant support from the Georgia research alliance, Georgia venture fund, and the BioMed Investor Network



Our vision





We are focused on the development of innovative new drugs to address under-served disease states, our primary focus is in the field of dermatology our

lead compound is currently being investigated in a phase 2 clinical study for the treatment of rosacea




MARKET POTENTIAL





The world-wide dermatology market is expected to grow to $22.7 billion by 2017 with the key drivers of growth being driven by innovation in chronic disease states such as psoriasis. Our compound is a first-in-class proteasome inhibitor for the treatment of rosacea and other topical skin diseases. It offers the potential to transform the value of the rosacea market through innovation to one of the largest segments in the dermatology market. Additionally the compound has promise as a therapeutic targeting Psoriasis, Skin aging, Acne, by breaking the inflammatory cascade associated with these disease states.

​

The combined estimated market potential for our compound is expected to exceed $500 million dollars in US sales annually



ABOUT ROSACEA





Rosacea is a dermato-ophthalmic condition that affects approximately 43 million in the US and Europe. It primarily affects the face and eyes and is characterized by the appearance of inflammatory lesions (papules and pustules), erythema (skin redness), and telandiectasia (spider veins). If all out progress tomorrow it is severe condition, rosacea can cause itching, pain and thickening of the skin.

Without treatment it may progress into a severe skin condition that can cause itching, pai, and thickening of the skin. No current therapeutics inhibit the transcription factor nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation associated with rosacea.



Our Partners



1005 Alderman Drive
Suite 104
Alpharetta, GA 3005


CALL: 678-812-1492



Accuitis, Inc.